Q2Pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR) bacteria to be used in conjunction with commonly used antibiotics or as stand-alone medications.
Our lead compound, F19 has shown promise in combating deadly MDR bacterial infections. Whereas antibiotics kill bacteria, as an antivirulent, F19 inhibits bacterial toxin release, allowing the immune system to do its job more effectively, resolving the infection. F19 has been shown to potentiate antibiotic efficacy, even to antibiotics that the pathogen is otherwise resistant. Recent experiments have demonstrated F19’s potent effects on several of the most common and deadly MDR bacteria.
F19 disarms bacteria of their virulence factors by targeting the staphylococcal transcription factor AgrA and suppressing the transcription of genes of the arg operon.
NEWS & PUBLICATIONS
Case Western Reserve University’s Biochemistry Department team is partnering with Q2Pharma to develop antivirulence agents that disarm bacteria of deadly toxins.
Learn more about the Q2Pharma management team and our distinguished scientific advisory board.
Q2Pharma is working towards satisfying an unmet need for more effective antimicrobial treatments for MDR bacteria. Our novel antivirulence agent, F19, can combat antibiotic resistant bacteria such as MRSA and Clostridium difficile. In vitro studies have shown that MRSA bacteria don’t develop resistance to F19 after 28 days in culture.
Q2Pharma Management Team Leaders
MBA, B.Sc, Co-founder and CEO
PhD, Co-founder and CSO
MD, Co-founder and CMO
B.Sc, Co-founder and Chief RA
B.Pharm, MBA; VP CMC